Microarray-based cancer prediction using soft computing approach

Cancer Informatics

Volumn 7, Issue , 2009, Pages 123-139

  Wang, Xiaosheng ^a   Gotoh, Osamu ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Cancer prediction; Decision rules; Feature selection; Gene expression profiles; Rough set theory; Soft computing

Indexed keywords

ARTICLE; B CELL LYMPHOMA; CANCER MODEL; CENTRAL NERVOUS SYSTEM TUMOR; COLON TUMOR; CONTROLLED STUDY; GENE EXPRESSION; GENETIC SCREENING; GENETIC SELECTION; HUMAN; LARGE CELL LYMPHOMA; LUNG CANCER; MARKER GENE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PATHOGENESIS; PREDICTION; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM CANCER; COLON CANCER; DECISION TREE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSE LARGE B CELL LYMPHOMA; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ALGORITHM; GENETIC CORRELATION; LEARNING ALGORITHM; MALIGNANT NEOPLASM; PREDICTIVE VALUE; SIGNAL NOISE RATIO; SOFT COMPUTING; STATISTICAL ANALYSIS; UPREGULATION;

TUMOR MARKER;

EID: 77649243439     PISSN: 11769351     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/cin.s2655     Document Type: Article

References (111)

1. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270(5235):467-70.
2. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286(5439):531-7.
3. Xing EP, Jordan MI, Karp RM. Feature selection for high-dimensional genomic microarray data. In: the Eighteenth International Conference on Machine Learning: 2001; Williams College, MA: Morgan Kaufmann Publishers Inc., San Francisco, U.S.A. 2001:601-8.
4. Simon R. Supervised analysis when the number of candidate feature (p) greatly exceeds the number of cases (n). ACM SIGKDD Explorations Newsletter. 2003;5(2):31-6.
5. Quinlan J: Induction of decision trees. Machine Learning. 1986;1:81-106.
6. Pawlak Z. Rough sets. International Journal of Computer and Information Sciences. 1982;11:341-56.
7. Li J, Wong L. Identifying good diagnostic gene groups from gene expression profiles using the concept of emerging patterns. Bioinformatics. 2002;18(5):725-34.
8. Sun L, Miao D, Zhang H. Efficient gene selection with rough sets from gene expression data. In: the 3rd International Conference on Rough Sets and Knowledge Technology: 2008:164-71.
9. Li D, Zhang W. Gene selection using rough set theory. In: the 1st International Conference on Rough Sets and Knowledge Technology: 2006:778-85.
10. Momin BF, Mitra S. Reduct generation and classification of gene expression data. In: First International Conference on Hybrid Information Technology. 2006:699-708.
11. Banerjee M, Mitra S, Banka H. Evolutinary-rough feature selection in gene expression data. IEEE Transaction on Systems, Man, and Cybernetics, Part C: Application and Reviews. 2007(37):622-32.
12. Tan AC, Gilbert D. Ensemble machine learning on gene expression data for cancer classification. Appl Bioinformatics. 2003;2(3 Suppl):S75-83.
13. Li J, Liu H, Downing JR, Yeoh AE, Wong L. Simple rules underlying gene expression profiles of more than six subtypes of acute lymphoblastic leukemia (ALL) patients. Bioinformatics. 2003;19(1):71-8.
14. Cong G, Tan KL, KH Tung A, Xu X. Mining top-k covering rule groups for gene expression data. In: the ACM SIGMOD International Conference on Management of Data: 2005:670-81.
15. Geman D, d'Avignon C, Naiman DQ, Winslow RL. Classifying gene expression profiles from pairwise mRNA comparisons. Stat Appl Genet Mol Biol. 2004;3:Article 19.
16. Gordon GJ, Jensen RV, Hsiao LL, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 2002;62(17):4963-7.
17. Pawlak Z. Rough sets-Theoretical aspects of reasoning about data, vol. 9. Dordrecht; Boston: Kluwer Academic Publishers; 1991.
18. Yu L, Liu H. Redundancy based feature selection for microarray data. In: the Tenth ACM SIGKDD Conference on Knowledge Discovery and Data Mining: 2004:737-42.
19. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415(6870):436-42.
20. Zhang LJ, Li ZJ, Hu XH. A Hybrid Gene Selection Method for Cancer Classification. In: VLDB Workshop on Data Mining in Bioinformatics: 2007; Vienna, Austria; 2007.
21. Fayyad UM, Irani KB. Multi-interval discretization of continuous-valued attributes for classification learning. In: the 13th International Joint Conference of Artificial Intelligence: 1993:1022-7.
22. Alon U, Barkai N, Notterman DA, et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A. 1999;96(12):6745-50.
23. Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of nonsmall cell lung cancer and correlation with disease-free survival. Cancer Res. 2002;62(11):3005-8.
24. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68-74.
25. Zhang D, Harry GJ, Blackshear PJ, Zeldin DC. G-protein pathway suppressor 2 (GPS2) interacts with the regulatory factor X4 variant 3 (RFX4-v3) and functions as a transcriptional co-activator. J Biol Chem. 2008;283(13):8580-90.
26. Newman LS, McKeever MO, Okano HJ, Darnell RB. Beta-NAP, a cerebellar degeneration antigen, is a neuron-specific vesicle coat protein. Cell. 1995;82(5):773-83.
27. Lipkowitz S, Gobel V, Varterasian ML, Nakahara K, Tchorz K, Kirsch IR. A comparative structural characterization of the human NSCL-1 and NSCL-2 genes. Two basic helix-loop-helix genes expressed in the developing nervous system. J Biol Chem. 1992;267(29):21065-71.
28. Jiang W, Li X, Rao S, et al. Constructing disease-specific gene networks using pair-wise relevance metric: application to colon cancer identifies interleukin 8, desmin and enolase 1 as the central elements. BMC Syst Biol. 2008;2:72.
29. Klieveri L, Fehres O, Griffini P, Van Noorden CJ, Frederiks WM. Promotion of colon cancer metastases in rat liver by fish oil diet is not due to reduced stroma formation. Clin Exp Metastasis. 2000;18(5):371-77.
30. Wang Q, Williamson M, Bott S, et al. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene. 2007;26(45): 6560-65.
31. Hirasawa Y, Arai M, Imazeki F, et al. Methylation status of genes upregulated by demethylating agent 5-aza-2'-deoxycytidine in hepatocellular carcinoma. Oncology. 2006;71(1-2):77-85.
32. Sato N, Fukushima N, Matsubayashi H, Goggins M. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene. 2004;23(8): 1531-8.
33. Schauer IG, Ressler SJ, Rowley DR. Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model. Prostate. 2009;69(4):373-84.
34. Bendrik C, Dabrosin C. Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol. 2009; 182(1):371-8.
35. Negaard HF, Iversen N, Bowitz-Lothe IM, et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia. 2009;23(1):162-9.
36. Chikazawa M, Inoue K, Fukata S, Karashima T, Shuin T. Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiology. 2008;75(6):335-45.
37. Lurje G, Zhang W, Schultheis AM, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol. 2008;19(10):1734-41.
38. Sullivan MM, Sage EH. Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. Int J Biochem Cell Biol. 2004;36(6):991-6.
39. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem. 2004;92(4):679-90.
40. Lau CP, Poon RT, Cheung ST, Yu WC, Fan ST. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol. 2006;210(4):459-68.
41. Esposito I, Kayed H, Keleg S, et al. Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia. 2007;9(1):8-17.
42. Bendik I, Schraml P, Ludwig CU. Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Res. 1998;58(4):626-9.
43. Claeskens A, Ongenae N, Neefs JM, et al. Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer. 2000;82(6):1123-30.
44. Nelson PS, Plymate SR, Wang K, et al. Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Res. 1998;58(2):232-6.
45. Zhang J, Guo H, Mi Z, et al. EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells. Exp Cell Res. 2009;315(2):304-12.
46. Umeda D, Yano S, Yamada K, Tachibana H. Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor. J Biol Chem. 2008;283(6):3050-8.
47. Rho SB, Park YG, Park K, Lee SH, Lee JH. A novel cervical cancer suppressor 3 (CCS-3) interacts with the BTB domain of PLZF and inhibits the cell growth by inducing apoptosis. FEBS Lett. 2006;580(17):4073-80.
48. Frum R, Busby SA, Ramamoorthy M, et al. HDM2-binding partners: interaction with translation elongation factor EF1alpha. J Proteome Res. 2007;6(4):1410-7.
49. Gopalkrishnan RV, Su ZZ, Goldstein NI, Fisher PB. Translational infidelity and human cancer: role of the PTI-1 oncogene. Int J Biochem Cell Biol. 1999;31(1):151-62.
50. Schafer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci. 1996;21(4):134-40.
51. Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci. 2002;7:d1356-68.
52. Melle C, Ernst G, Schimmel B, et al. Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma. Int J Oncol. 2006;28(1):195-200.
53. Stulik J, Koupilova K, Osterreicher J, et al. Protein abundance alterations in matched sets of macroscopically normal colon mucosa and colorectal carcinoma. Electrophoresis. 1999;20(18):3638-46.
54. Reichling T, Goss KH, Carson DJ, et al. Transcriptional profiles of intestinal tumors in Apc(Min) mice are unique from those of embryonic intestine and identify novel gene targets dysregulated in human colorectal tumors. Cancer Re. 2005;65(1):166-76.
55. Chaurand P, DaGue BB, Pearsall RS, Threadgill DW, Caprioli RM. Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry. Proteomics. 2001;1(10):1320-6.
56. Tanaka M, Adzuma K, Iwami M, Yoshimoto K, Monden Y, Itakura M. Human calgizzarin; one colorectal cancer-related gene selected by a large scale random cDNA sequencing and northern blot analysis. Cancer Lett. 1995;89(2):195-200.
57. Varga AE, Stourman NV, Zheng Q, et al. Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta. Oncogene. 2005;24(32):5043-52.
58. He XX, Chen K, Yang J, et al. Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med. 2009;15(1-2):1-10.
59. Ren Y, Law S, Huang X, et al. Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg. 2005;242(1):55-63.
60. Legendre H, Decaestecker C, Nagy N, et al. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol. 2003;16(5):491-504.
61. Ren Y, Tsui HT, Poon RT, et al. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer. 2003;107(1):22-9.
62. Wilson JM, Coletta PL, Cuthbert RJ, et al. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology. 2005;129(5):1485-503.
63. Xu X, Wang B, Ye C, et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett. 2008;261(2):147-57.
64. Imai K, Hirata S, Irie A, et al. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res. 2008;14(20):6487-95.
65. Bauer R, Dowejko A, Driemel O, Bosserhoff AK, Reichert TE. Truncated P-cadherin is produced in oral squamous cell carcinoma. Febs J. 2008;275(16):4198-210.
66. Ben Hamida A, Labidi IS, Mrad K, et al. Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. BMC Cancer. 2008;8:28.
67. Rocha AS, Soares P, Machado JC, et al. Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoexpression and marked abnormalities of E-cadherin/catenins complex. Virchows Arch. 2002;440(5):498-504.
68. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res. 2005;11(16):5869-77.
69. Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD. Cadherin switching in ovarian cancer progression. Int J Cancer. 2003;106(2): 172-7.
70. Lo Muzio L, Campisi G, Farina A, et al. P-cadherin expression and survival rate in oral squamous cell carcinoma: an immunohistochemical study. BMC Cancer. 2005;5:63.
71. Reed CE, Graham A, Hoda RS, et al. A simple two-gene prognostic model for adenocarcinoma of the lung. J Thorac Cardiovasc Surg. 2008;135(3):627-34.
72. Bauer R, Bosserhoff AK. Functional implication of truncated P-cadherin expression in malignant melanoma. Exp Mol Pathol. 2006;81(3): 224-30.
73. Makino H, Tajiri T, Miyashita M, et al. Differential expression of TCEAL1 in esophageal cancers by custom cDNA microarray analysis. Dis Esophagus. 2005;18(1):37-40.
74. Hou YF, Yuan ST, Li HC, et al. ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene. 2004;23(34): 5799-806.
75. Sohda M, Ishikawa H, Masuda N, et al. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer. 2004;110(6):838-44.
76. Kim YB, Ki SW, Yoshida M, Horinouchi S. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J Antibiot (Tokyo). 2000;53(10):1191-200.
77. Santos AM, Sousa H, Pinto D, et al. Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur J Cancer. 2006;42(7):958-63.
78. Lee JH, Horak CE, Khanna C, et al. Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility. Cancer Res. 2008;68(3):639-44.
79. Parise P, Finocchiaro G, Masciadri B, et al. Lap2alpha expression is controlled by E2F and deregulated in various human tumors. Cell Cycle. 2006;5(12):1331-41.
80. Weber PJ, Eckhard CP, Gonser S, Otto H, Folkers G, Beck-Sickinger AG. On the role of thymopoietins in cell proliferation. Immunochemical evidence for new members of the human thymopoietin family. Biol Chem. 1999;380(6):653-60.
81. Xiao D, Wang K, Zhou J, et al. Inhibition of fibroblast growth factor 2-induced apoptosis involves survivin expression, protein kinase C alpha activation and subcellular translocation of Smac in human small cell lung cancer cells. Acta Biochim Biophys Sin (Shanghai). 2008; 40(4):297-303.
82. Kempkensteffen C, Hinz S, Christoph F, et al. Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. J Cancer Res Clin Oncol. 2008;134(5):543-50.
83. Mizutani Y, Nakanishi H, Yamamoto K, et al. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol. 2005;23(3):448-54.
84. Yan Y, Mahotka C, Heikaus S, et al. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br J Cancer. 2004;91(7):1349-57.
85. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002;8(8): 808-15.
86. Yang L, Mashima T, Sato S, et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res. 2003;63(4):831-7.
87. Vogler M, Giagkousiklidis S, Genze F, Gschwend JE, Debatin KM, Fulda S. Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. Oncogene. 2005;24(48): 7190-202.
88. Mao HL, Liu PS, Zheng JF, et al. Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro. Pharmacol Res. 2007;56(6):483-92.
89. Checinska A, Hoogeland BS, Rodriguez JA, Giaccone G, Kruyt FA. Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation. Exp Cell Res. 2007;313(6):1215-24.
90. McNeish IA, Lopes R, Bell SJ, et al. Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp Cell Res. 2005;302(1):69-82.
91. Martinez-Velazquez M, Melendez-Zajgla J, Maldonado V. Apoptosis induced by cAMP requires Smac/DIABLO transcriptional upregulation. Cell Signal. 2007;19(6):1212-20.
92. Sekimura A, Konishi A, Mizuno K, et al. Expression of Smac/DIABLO is a novel prognostic marker in lung cancer. Oncol Rep. 2004;11(4): 797-802.
93. Wang Y, Broderick P, Webb E, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet. 2008;40(12):1407-9.
94. Inaba T, Roberts WM, Shapiro LH, et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science. 1992;257(5069):531-4.
95. Muris JJ, Meijer CJ, Ossenkoppele GJ, Vos W, Oudejans JJ. Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma. Hematol Oncol. 2006;24(3):97-104.
96. Mishra S, Murphy LJ. The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity. Biochem Biophys Res Commun. 2006;339(2):726-30.
97. Mangala LS, Arun B, Sahin AA, Mehta K. Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer. 2005;4:33.
98. Xu L, Begum S, Hearn JD, Hynes RO. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci U S A. 2006;103(24):9023-8.
99. Goke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol. 2004;287(6):C1541-6.
100. Jin H, Kim TH, Hwang SK, et al. Aerosol delivery of urocanic acidmodifi ed chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol Cancer Ther. 2006;5(4):1041-9.
101. Schmid T, Jansen AP, Baker AR, Hegamyer G, Hagan JP, Colburn NH. Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res. 2008;68(5):1254-60.
102. Wang Q, Sun Z, Yang HS: Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells. Oncogene. 2008;27(11):1527-35.
103. Yang HS, Matthews CP, Clair T, et al. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol. 2006;26(4):1297-306.
104. Lankat-Buttgereit B, Lenschen B, Schmidt H, Goke R. The action of Pdcd4 may be cell type specific: evidence that reduction of dUTPase levels might contribute to its tumor suppressor activity in Bon-1 cells. Apoptosis. 2008;13(1):157-64.
105. Holte RC. Very simple classification rules perform well on most commonly used datasets. Machine Learning. 1993:63-91.
106. Witten IH, Frank E. Data mining: practical machine learning tools and techniques (second edition): Morgan Kaufmann; 2005.
107. Wang Y, Makedon FS, Ford JC, Pearlman J. HykGene: a hybrid approach for selecting marker genes for phenotype classification using microarray gene expression data. Bioinformatics. 2005;21(8):1530-7.
108. Antoniadis A, Lambert-Lacroix S, Leblanc F. Effective dimension reduction methods for tumor classification using gene expression data. Bioinformatics. 2003;19(5):563-70.
109. Sun L, Miao D, Zhang H. Gene Selection with Rough Sets for Cancer Classification. In: Fourth International Conference on Fuzzy Systems and Knowledge Discovery. 2007:167-72.
110. Ding C, Peng H. Minimum redundancy feature selection from microarray gene expression data. J Bioinform Comput Biol. 2005;3(2):185-205.
111. Yu L, Liu H. Redundancy Based Feature Selection for Microarray Data. In: the tenth ACM SIGKDD international conference on Knowledge discovery and data mining: 2004. 2004:737-42.